Outcomes in Reoperated Low-Grade Gliomas

Neurosurgery

Volumn 77, Issue 2, 2015, Pages 175-184

  Ramakrishna, Rohan ^a   Hebb, Adam ^b   Barber, Jason ^c   Rostomily, Robert ^c   Silbergeld, Daniel ^c  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b Colorado Neurological Institute ^*  (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Astrocytoma; Glioblastoma; LGG; Low grade glioma; Oligoastrocytoma; Oligodendroglioma; Surgery for glioma

Indexed keywords

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CLINICAL EVALUATION; COHORT ANALYSIS; FEMALE; FOLLOW UP; GLIOMA; HUMAN; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REOPERATION; RETROSPECTIVE STUDY; SURVIVAL RATE; AGE; AGED; BRAIN NEOPLASMS; DISEASE FREE SURVIVAL; MULTIMODALITY CANCER THERAPY; NEUROSURGERY; PROGNOSIS; SEX DIFFERENCE; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; TUMOR RECURRENCE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; COHORT STUDIES; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GLIOMA; HUMANS; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEUROSURGICAL PROCEDURES; PROGNOSIS; REOPERATION; RETROSPECTIVE STUDIES; SEX FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84937437992     PISSN: 0148396X     EISSN: 15244040     Source Type: Journal    
DOI: 10.1227/NEU.0000000000000753     Document Type: Article

References (69)

1. Baumert BG, Stupp R. Low-grade glioma: a challenge in therapeutic options: the role of radiotherapy. Ann Oncol. 2008;19(suppl 7):vii217-vii222.
2. Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol. 2002;20(8):2076-2084.
3. Bauman G, Lote K, Larson D, et al. Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis. Int J Radiat Oncol Biol Phys. 1999;45(4):923-929.
4. Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the longterm outcome of low-grade hemispheric gliomas. J Clin Oncol. 2008;26(8): 1338-1345.
5. Duffau H. Awake surgery for nonlanguage mapping. Neurosurgery. 2010;66(3): 523-528; discussion 528-529.
6. Berger MS, Deliganis AV, Dobbins J, Keles GE. The effect of extent of resection on recurrence in patients with low-grade cerebral hemisphere gliomas. Cancer. 1994;74(6):1784-1791.
7. Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas. JAMA. 2012;308(18):1881-1888.
8. van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet. 2005;366(9490):985-990.
9. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997-1003.
10. Keles GE, Chang EF, Lamborn KR, et al. Volumetric extent of resection and residual contrast enhancement on initial surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. J Neurosurg. 2006;105(1): 34-40.
11. Laws ER Jr, Taylor WF, Clifton MB, Okazaki H. Neurosurgical management of low-grade astrocytoma of the cerebral hemispheres. J Neurosurg. 1984;61(4): 665-673.
12. Leighton C, Fisher B, Bauman G, et al. Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. J Clin Oncol. 1997;15(4): 1294-1301.
13. Nakamura M, Konishi N, Tsunoda S, et al. Analysis of prognostic and survival factors related to treatment of low-grade astrocytomas in adults. Oncology. 2000;58 (2):108-116.
14. Philippon JH, Clemenceau SH, Fauchon FH, Foncin JF. Supratentorial low-grade astrocytomas in adults. Neurosurgery. 1993;32(4):554-559.
15. Rajan B, Pickuth D, Ashley S, et al. The management of histologically unverified presumed cerebral gliomas with radiotherapy. Int J Radiat Oncol Biol Phys. 1994; 28(2):405-413.
16. Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol. 2002;20(9): 2267-2276.
17. Shaw EG, Daumas-Duport C, Scheithauer BW, et al. Radiation therapy in the management of low-grade supratentorial astrocytomas. J Neurosurg. 1989;70(6): 853-861.
18. Yeh SA, Ho JT, Lui CC, Huang YJ, Hsiung CY, Huang EY. Treatment outcomes and prognostic factors in patients with supratentorial low-grade gliomas. Br J Radiol. 2005;78(927):230-235.
19. Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery. 2008;62(4):753-764; discussion 764-766.
20. Lamborn KR, Chang SM, Prados MD. Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro Oncol. 2004;6(3): 227-235.
21. Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys. 1996;36(3):549-556.
22. Shaw EG, Tatter SB, Lesser GJ, Ellis TL, Stanton CA, Stieber VW. Current controversies in the radiotherapeutic management of adult low-grade glioma. Semin Oncol. 2004;31(5):653-658.
23. Sijens PE, Heesters MA, Enting RH, et al. Diffusion tensor imaging and chemical shift imaging assessment of heterogeneity in low-grade glioma under temozolomide chemotherapy. Cancer Invest. 2007;25(8):706-710.
24. Kaloshi G, Benouaich-Amiel A, Diakite F, et al. Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology. 2007;68(21):1831-1836.
25. Idbaih A, Carvalho Silva R, Criniere E, et al. Genomic changes in progression of low-grade gliomas. J Neurooncol. 2008;90(2):133-140.
26. Ahmadi R, Dictus C, Hartmann C, et al. Long-term outcome and survival of surgically treated supratentorial low-grade glioma in adult patients. Acta Neurochir (Wien). 2009;151(11):1359-1365.
27. Kleihues P, Louis DN, Scheithauer BW, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol. 2002;61(3):215-225; discussion 226-229.
28. Hebb AO, Yang T, Silbergeld DL. The sub-pial resection technique for intrinsic tumor surgery. Surg Neurol Int. 2011;2:180.
29. McGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas. Neurosurgery. 2008;63(4):707; author reply 707-708.
30. Schomas DA, Laack NN, Rao RD, et al. Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-up at Mayo Clinic. Neuro Oncol. 2009; 11(4):437-445.
31. Jaeckle KA, Decker PA, Ballman KV, et al. Transformation of low-grade glioma and correlation with outcome: an NCCTG database analysis. J Neurooncol. 2011; 104(1):253-259.
32. Berger MS, Rostomily RC. Low-grade gliomas: functional mapping resection strategies, extent of resection, and outcome. J Neurooncol. 1997;34(1):85-101.
33. Lang FF, Gilbert MR. Diffusely infiltrative low-grade gliomas in adults. J Clin Oncol. 2006;24(8):1236-1245.
34. Cavaliere R, Lopes MB, Schiff D. Low-grade gliomas: an update on pathology and therapy. Lancet Neurol. 2005;4(11):760-770.
35. Keles GE, Lamborn KR, Berger MS. Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome. J Neurosurg. 2001;95(5):735-745.
36. Piepmeier J, Baehring JM. Surgical resection for patients with benign primary brain tumors and low-grade gliomas. J Neurooncol. 2004;69(1-3):55-65.
37. Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeondetermined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial. J Neurosurg. 2008;109(5):835-841.
38. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001;95(2):190-198.
39. Suneja G, Alonso-Basanta M, Lustig R, Lee JY, Bekelman JE. Postoperative radiation therapy for low-grade glioma: patterns of care between 1998 and 2006. Cancer. 2012;118(15):3735-3742.
40. Arvinda HR, Kesavadas C, Sarma PS, et al. Glioma grading: sensitivity, specificity, positive and negative predictive values of diffusion and perfusion imaging. J Neurooncol. 2009;94(1):87-96.
41. Bulik M, Jancalek R, Vanicek J, Skoch A, Mechl M. Potential of MR spectroscopy for assessment of glioma grading. Clin Neurol Neurosurg. 2013;115(2):146-153.
42. Danchaivijitr N,Waldman AD, Tozer DJ, et al. Low-grade gliomas: do changes in rCBV measurements at longitudinal perfusion-weighted MR imaging predict malignant transformation? Radiology. 2008;247(1):170-178.
43. Hlaihel C, Guilloton L, Guyotat J, Streichenberger N, Honnorat J, Cotton F. Predictive value of multimodality MRI using conventional, perfusion, and spectroscopy MR in anaplastic transformation of low-grade oligodendrogliomas. J Neurooncol. 2010;97(1):73-80.
44. Lev MH, Ozsunar Y, Henson JW, et al. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. AJNR Am J Neuroradiol. 2004;25(2):214-221.
45. Meyzer C, Dhermain F, Ducreux D, et al. A case report of pseudoprogression followed by complete remission after proton-beam irradiation for a low-grade glioma in a teenager: the value of dynamic contrast-enhanced MRI. Radiat Oncol. 2010;5:9.
46. van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol. 2013;31(3):344-350.
47. Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. 2013;31(3):337-343.
48. Kouwenhoven MC, Kros JM, French PJ, et al. 1p/19q Loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment. Eur J Cancer. 2006;42(15):2499-2503.
49. Levin N, Lavon I, Zelikovitsh B, et al. Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6- methylguanine DNA methyltransferase protein expression. Cancer. 2006;106(8): 1759-1765.
50. Walker C, Haylock B, Husband D, et al. Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors. Neurology. 2006;66(11):1661-1667.
51. van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet. 2005;366(9490):985-990.
52. Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. J Clin Oncol. 2012;30(25): 3065-3070.
53. Johnson BE, Mazor T, Hong C, et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science. 2014;343(6167):189-193.
54. Yang P, Wang Y, Peng X, et al. Management and survival rates in patients with glioma in China (2004-2010): a retrospective study from a single-institution. J Neurooncol. 2013;113(2):256-266.
55. Karim AB, Afra D, Cornu P, et al. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis. Int J Radiat Oncol Biol Phys. 2002;52(2):316-324.
56. Gorlia T, Wu W, Wang M, et al. New validated prognostic models and prognostic calculators in patients with low-grade gliomas diagnosed by central pathology review: a pooled analysis of EORTC/RTOG/NCCTG phase III clinical trials. Neuro Oncol. 2013;15(11):1568-1579.
57. Pamir MN, Ozduman K, Yildiz E, Sav A, Dincer A. Intraoperative magnetic resonance spectroscopy for identification of residual tumor during low-grade glioma surgery. J Neurosurg. 2013;181(6):1191-1198.
58. Sanai N, Snyder LA, Honea NJ, et al. Intraoperative confocal microscopy in the visualization of 5-aminolevulinic acid fluorescence in low-grade gliomas. J Neurosurg. 2011;115(4):740-748.
59. Bao Z, Zhang C, Yan W, et al. BMP4, a strong better prognosis predictor, has a subtype preference and cell development association in gliomas. J Transl Med. 2013;11:100.
60. Chen D, Persson A, Sun Y, et al. Better prognosis of patients with glioma expressing FGF2-dependent PDGFRA irrespective of morphological diagnosis. PLoS One. 2013;8(4):e61556.
61. Kim YH, Nobusawa S, Mittelbronn M, et al. Molecular classification of low-grade diffuse gliomas. Am J Pathol. 2010;177(6):2708-2714.
62. Marko NF, Prayson RA, Barnett GH, Weil RJ. Integrated molecular analysis suggests a three-class model for low-grade gliomas: a proof-of-concept study. Genomics. 2010;95(1):16-24.
63. Tian L, Zhang Y, Chen Y, Cai M, Dong H, Xiong L. EMMPRIN is an independent negative prognostic factor for patients with astrocytic glioma. PLoS One. 2013;8(3):e58069.
64. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98-110.
65. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006;9(3):157-173.
66. Boots-Sprenger SH, Sijben A, Rijntjes J, et al. Significance of complete 1p/19q codeletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution. Mod Pathol. 2013.
67. Weiler M, Wick W. Molecular predictors of outcome in low-grade glioma. Curr Opin Neurol. 2012; 25(6): 767-773.
68. Chinnaiyan P, Kensicki E, Bloom G, et al. The metabolomic signature of malignant glioma reflects accelerated anabolic metabolism. Cancer Res. 2012;72 (22):5878-5888.
69. Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg. 2011; 115(1):3-8.